Leukaemia - acute lymphoblastic leukaemia

The PBS subsidises blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib for patients with acute lymphoblastic leukaemia.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib under the National Health Act 1953, section 85 and section 100 for patients with acute lymphoblastic leukaemia (ALL).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib.

Section 100 arrangements

Blinatumomab and inotuzumab ozogamicin

These items are only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public hospital.

These items aren’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for initial treatment

Blintumomab

Apply for initial (induction) authority approval to prescribe PBS-subsidised blinatumomab to treat ALL in writing and either:

All written applications must include the completed:

Dasatinib

Apply for first line initial authority approval to prescribe PBS-subsidised dasatinib to treat ALL in writing and either:

All written applications must include the completed:

Apply for second line initial authority approval to prescribe PBS-subsidised dasatinib to treat ALL in writing and either:

All written applications must include the completed:

Imatinib

Apply for first line initial authority approval to prescribe PBS-subsidised imatinib to treat ALL by calling the PBS Complex Drugs Programs enquiry line.

Inotuzumab ozogamicin

Apply for initial authority approval to prescribe PBS-subsidised inotuzumab ozogamicin to treat ALL in writing and either:

All written applications must include the completed:

Ponatinib

Apply for initial authority approval to prescribe PBS-subsidised ponatinib to treat ALL in writing and either:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised blinatumomab, dasatinib, inotuzumab ozagamicin and ponatinib can be made either:

Continuing PBS-subsidised treatment with imatinib is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 November 2023.
QC 33146